Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
{{output}}
Background: PADA-1 was the first prospective randomized trial to show that early therapeutic targeting of bESR1mut mutations with fulvestrant provides significant clinical benefit in patients with ER+/HER2- advanced breast cancer... ...
